New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
16:22 EDTATHN, ODP, NUS, TWTR, TSLA, MRK, GRPN, AOL, TGT, BAYRY, FEYE, WFM, AAPLMarket finishes week mixed following earnings, Fed commentary
The major averages ended the week mixed after Fed Chair Janet Yellen testified before Congress and a number of major companies reported weak earnings. MACRO NEWS: The labor market is "far from satisfactory" and inflation remains below the Fed's target, Yellen told Congress. Responding to questions on the Fed's exit strategy, Yellen said the FOMC plans to continue reducing QE purchases as long as Fed objectives are being met, but that a high degree of monetary accommodation is still warranted... U.S. economic data was mostly upbeat, with weekly jobless claims coming in better than expected and a services sector index beating the consensus outlook. However, first quarter productivity was estimated to have declined 1.7%, which was worse than the 1.1% drop predicted by economists... Away from the U.S., Chinese trade data for April was better than expected, but an index that measures the country's services sector fell slightly in April versus March. In Europe, ECB President Mario Draghi said the governing council was "comfortable" with easing at its next policy meeting. COMPANY NEWS: Tesla (TSLA), AOL (AOL), Whole Foods (WFM), Nu Skin (NUS), FireEye (FEYE), and Groupon (GRPN) were among the companies whose stocks fell after they reported earnings. Conversely, Office Depot (ODP), Humana (HUM) and Electronics Arts (EA) rose following their results... Twitter (TWTR) tumbled this week after over 450M of its shares, which represent around 80% of the total shares outstanding, were permitted to be sold without the restrictions that were put in place by the company’s initial public offering. Other previously high flying Internet stocks also continued their recent descent... Shares of Apple (AAPL) were in-focus after Financial Times said that the iPhone and iPad maker is in talks to acquire Beats Electronics, the headphone maker co-founded by rapper and record producer Dr. Dre, for over $3B... Bayer (BAYRY) and Merck (MRK) announced the latest in a series of major deals in the pharmaceutical industry, with Bayer agreeing to acquire Merck's consumer care business for $14.2B... Target (TGT) announced that CEO Gregg Steinhafel would leave the company effective immediately. The credit card data breach that hit the company late last year occurred on Steinhafel's watch... Well-known investor David Einhorn said he is short shares of athenahealth (ATHN). Athenahealth is not a software company, but an outsourcing company, and expectations for its operating margins are too high, said Einhorn. INDEXES: The Dow was up 0.4% to 16,583.34, the S&P 500 was down 0.1% to 1,878.48, and the Nasdaq was down 1.2% to 4,071.87.
News For TSLA;AAPL;TGT;TWTR;WFM;AOL;NUS;FEYE;GRPN;ODP;BAYRY;MRK;ATHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
November 10, 2014
16:00 EDTAAPL, TSLA, TWTROptions Update; November 10, 2014
Subscribe for More Information
14:38 EDTFEYEU.S. Postal Service suffered cyberattack, NY Times reports
Subscribe for More Information
12:42 EDTFEYE, AAPLFireEye details hack attack found on Apple operating system
Subscribe for More Information
12:39 EDTFEYE, AAPLFireEye has uncovered iOS flaw that leaves devices vulnerable, CNBC reports
Subscribe for More Information
11:35 EDTWFMStocks with call strike movement; WFM KORS
Whole Foods (WFM) February 52.5 call option implied volatility increased 2% to 28, Michael Kors (KORS) May 85 call option implied volatility decreased 2% to 31 according to IVolatility.
10:30 EDTFEYEFireEye advances after JPMorgan adds to Focus List
Subscribe for More Information
10:04 EDTTGTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:35 EDTAAPLActive equity options trading
Subscribe for More Information
09:20 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTMRKGilead rises after Merck presents data on HCV combo
Subscribe for More Information
08:08 EDTTGTTarget upgraded at Stifel
Subscribe for More Information
07:34 EDTWFM, AAPLApple Pay seen making up 1% of Whole Foods transactions since launch, Dudas says
Subscribe for More Information
07:30 EDTFEYEFireEye added to Focus List, Akamai removed at JPMorgan
Subscribe for More Information
07:20 EDTMRKGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
07:12 EDTTWTRCA Technologies to hold a conference
CA World 2014 is being held in Las Vegas on November 9-12.
06:27 EDTAAPLGT Advanced accuses Apple of 'bait-and-switch' in unsealed documents, WSJ says
Subscribe for More Information
06:00 EDTAAPLApple implied volatility of 19 at lower end of index mean range
Subscribe for More Information
05:54 EDTWFMStocks with implied volatility movement; WFM AEO
Subscribe for More Information
05:54 EDTTGTTarget upgraded to Buy from Hold at Stifel
Subscribe for More Information
November 9, 2014
18:58 EDTMRKMerck presents interim data from C-SWIFT study
Merck announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus, HCV, infection. Preliminary findings in treatment-naïve HCV genotype 1- infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases, AASLD, Annual Meeting, also known as The Liver Meeting. “These interim data provide a compelling proof-of-concept for the potential of an eight- or six-week triple therapy course in treatment-naive patients with genotype 1 disease, including cirrhotic patients,” said Dr. Lawitz. “These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types.”
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use